Mycobacterium tuberculosis

Résumé

Mycobacterium tuberculosis – aussi nommée bacille de Koch (BK) en référence à son découvreur Robert Koch – est une espèce de bacille de la famille des Mycobacteriaceae. Sa structure la rapproche des bactéries à Gram positif bien qu'en pratique la coloration de Gram soit difficilement réalisable sur elle. C'est l'espèce type du genre Mycobacterium et l'agent infectieux responsable de la tuberculose humaine. Histoire La découverte de M. tuberculosis par Robert Koch en 1882 est considérée comme l'un des plus grands succès de la carrière de ce bactériologiste allemand : elle lui vaudra le prix Nobel de physiologie ou médecine de 1905 ainsi qu'une renommée internationale. Le génome de M. tuberculosis est séquencé pour la première en 1998 par S.T. Cole . Taxonomie Mycobacterium tuberculosis est l'espèce-type du genre Mycobacterium dont les contours ont été redéfinis en 2018 par des techniques de phylogénétique moléculaire. Décrite en par Zopf sous le nom de Bacteri

Source officielle

https://fr.wikipedia.org/wiki/Mycobacterium_tuberculosis

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Publications associées (100)

Publications associées

Chargement

Personnes associées (39)

Personnes associées

Chargement

Unités associées (10)

Unités associées

Chargement

Concepts associés (38)

Concepts associés

Chargement

Cours associés (4)

Cours associés

Chargement

Séances de cours associées (4)

Séances de cours associées

Chargement

Functional characterization of the virulence determinant ESX-1 from Mycobacterium tuberculosis

Paloma Julia Soler Arnedo

Tuberculosis (TB) is a chronic infectious disease that mainly affects the lungs and causes extensive human morbidity and mortality. It results from infection with Mycobacterium tuberculosis, a slow-growing intracellular pathogen that can replicate and survive inside macrophages. M. tuberculosis relies on the specialised ESX-1 secretion system to export virulence factors needed for intracellular spread and pathogenesis. The ESX-1 apparatus is a multi-subunit nanomachine composed of ~20 polypeptides including membrane proteins, ATPases, proteases, chaperones and substrates. Although many of the individual components of this secretion system have been characterised, the overall mechanism underlying ESX-1 secretion is still far from clear. To obtain a more comprehensive picture of the functioning of the ESX-1 apparatus, we have studied various components which were largely unexplored in M. tuberculosis. The structural component EccE1, the ESX-1 specific protein EspL and the transcriptional regulator WhiB6 have been investigated in this thesis using an integrative approach involving genetics, biochemistry, proteomics and microscopy. We have demonstrated that EccE1 is a membrane- and cell-wall associated protein critical for secretion of ESX-1 substrates and M. tuberculosis-mediated cell lysis. Deletion of eccE1 from the chromosome severely compromised secretion of EsxA, EsxB, EspA and EspC but not EspB. Localization studies using a florescent-fusion protein showed that EccE1 localises to the poles of M. tuberculosis in the presence of an active ESX-1 system. Our study also shows that EspL is a cytosolic protein needed for stabilising EspE, EspF and EspH, suggesting that it acts as a specific chaperone of the ESX-1 secretion system. Moreover, EspL was shown to interact with EspD and to be important for the secretion of ESX-1 substrates. Lack of EspL resulted in a growth defect ex vivo, loss of cytotoxicity and reduction of innate cytokine production demonstrating its critical role in M. tuberculosis virulence. Analysis of the transcriptional response revealed that the only gene deregulated in the absence of espL was whiB6, encoding a transcriptional factor that positively controls ESX-1 genes. To explore the role of this regulator in M. tuberculosis virulence, we generated a deletion mutant of whiB6 and discovered that its loss resulted in severe reduction of cytotoxicity ex vivo. Overall this investigation improves our current understanding of the ESX-1 secretion system and of the molecular basis of M. tuberculosis virulence. The increased knowledge of the complex interactions between the pathogen and the human host will hopefully translate into new strategies to control the spread of TB.

EPFL2018

Chargement

More Medicines for Tuberculosis: Fuelling Drug Discovery against Mycobacterium tuberculosis

Shi-Yan Caroline Foo

Tuberculosis (TB), whose etiological agent is Mycobacterium tuberculosis (M. tuberculosis), has plagued humanity since antiquity. Even with chemotherapy available today, TB is the leading cause of death due to an infectious disease. Modern day factors, such as the HIV epidemic and the emergence of drug-resistant TB strains, have redefined the complexities and challenges of tackling the TB pandemic. Current treatments for TB are lengthy, and poor adherence to such prolonged treatment further exacerbates the issue of drug resistance. Moreover, therapies for drug-resistant TB have low cure rates. There is therefore a pressing need for improved therapies that are short and efficacious against all TB strains, which can be achieved through new antimicrobials that are more potent and have novel mechanisms of action, in addition to being affordable, orally bioavailable, and without drug-drug interactions. Such new anti-TB drugs need to be discovered and developed through a long, risky, and costly process, in which attrition rates are high. While there are promising compounds currently being developed, including the benzothiazinones (BTZs), it is necessary to further populate and enhance the Global TB drug pipeline to ensure the availability of new drugs. This thesis aims to address this need through the discovery work of two new, highly promising families, the AX and PB compounds, and of BTZs. The piperazine-based AX analogs are easily synthesised and demonstrate potent activity against M. tuberculosis in vitro and in vivo. Their target, identified in this work, is the QcrB subunit of the cytochrome bc1-aa3 complex, a terminal oxidase of the mycobacterial respiratory chain. Notably, AX compounds are bactericidal in the absence of the alternate terminal oxidase, cytochrome bd. As this family interacts differently in the same binding site of QcrB as Q203, a drug candidate in clinical trials, AX compounds could potentially serve as a backup series for QcrB inhibitors. The PB family, derived from the natural product lapachol, is also easily synthesised and shows substantially improved activity against M. tuberculosis in vitro compared to the parent compound. PB analogs also demonstrated activity against the non-replicating bacillus and in infected macrophages. The mechanism of action of PB compounds relies on the F420 cofactor, although not on the F420-dependent nitroreductase Ddn, therefore this family has a novel mechanism of action which is highly specific to M. tuberculosis. To support the clinical development of PBTZ169, the mechanism of resistance to BTZs was further elucidated in this thesis. Five mutations at cysteine 387 of the target enzyme, DprE1, were identified as mediating resistance to BTZs, which would serve as resistance markers for clinical screening. The impact of these mutations on M. tuberculosis and on DprE1 was further characterised, revealing a fitness cost imposed on the bacillus intracellularly and reduced catalytic efficiency of the enzyme. This thesis additionally contributed to the characterisation of a PBTZ169 backup series and the design of an optimal regimen with other TB drugs. The compounds presented herein merit further optimisation so their full antibiotic potential may be realised for TB, and possibly for other mycobacterial diseases as well. Altogether, this thesis has contributed to the fuelling of drug discovery against M. tuberculosis, and a step towards more medicines for TB.

EPFL2018

Chargement

The fatal lung disease tuberculosis is caused by the airborne Mycobacterium tuberculosis, a versatile pathogen adapted to rapidly changing environments. Instead of being eradicated by phagocytic cells of its human host, bacilli tune macrophages to support their own growth and even mask their presence from the immune system for several decades. Rapid adjustment of gene expression is critical for bacterial survival and heavily relies on nucleoid-associated proteins (NAPs). NAPs contribute to active DNA management by altering the chromosomal topology through bending, bridging and looping the DNA. These conformational changes can bring distant genetic loci into close spatial proximity or influence DNA supercoiling and therefore accessibility of the transcription machinery. Apart from their architectural role, NAPs moreover act as global transcription factors by direct regulation of numerous genes. In M. tuberculosis, five proteins were assigned a role as NAP. Among these, EspR, HupB and Lsr2 are crucial not only for virulence but also for cellular metabolism. This thesis focuses on the NAPs mIHF and H-NS with the objective of determining their function and target regulon. Both proteins were investigated by means of genetic manipulation, phenotype assessment and structural studies, and the efficiency of a potential new anti-tuberculosis drug acting on Lsr2 was assessed. Chrysomycin, described as specific inhibitor of Lsr2-DNA complex formation, was found to intercalate into the DNA. The resulting toxic effect on both its target M. tuberculosis as well as on eukaryotic cells rendered further development of the compound as an anti-tuberculosis drug futile. We demonstrated that Rv3852, formerly annotated as H-NS, does not act as a NAP. Deletion of the rv3852 gene had no effect on the in vitro phenotype of M. tuberculosis, did not alter nucleoid spread nor position and had no influence on virulence in mice. The mIHF protein on the other hand is not only essential for active bacterial growth, but also indispensable for survival. Generation of a conditional knockdown mutant showed that depletion of mIHF led to elongated cells devoid of septa with abnormal DNA localization and finally to cell death. The target regulon of mIHF was thoroughly studied by mapping its binding sites on the bacterial genome and by identifying genes that were differentially expressed upon depletion of the protein. We found that mIHF has a strong effect on virulence gene expression and, similar to EspR, possesses a major binding site upstream of one of the main virulence factor operons espACD. Analysis of the transcriptional response revealed that mIHF is further involved in the bacterial response to the hostâs immune system, including control of nutrient pathways as well as global protein and nucleic acid synthesis. To define how mIHF interacts with DNA and influences its 3D organisation, the protein structure of mIHF was determined by nuclear magnetic resonance spectroscopy. Binding of mIHF introduced left-hand loops into linear as well as supercoiled DNA substrates, therefore unwinding condensed DNA. We identified two DNA binding domains in mIHF and showed that its stability increased substantially upon DNA binding. All together, the findings of this thesis contribute to a better understanding of the complex gene regulatory network of M. tuberculosis, advancing the knowledge necessary to eventually defeat tuberculosis, a disease that has plagued humanity for millennia.

EPFL2017

Chargement

Functional characterization of the virulence determinant ESX-1 from Mycobacterium tuberculosis

Paloma Julia Soler Arnedo

EPFL2018

More Medicines for Tuberculosis: Fuelling Drug Discovery against Mycobacterium tuberculosis

Shi-Yan Caroline Foo

EPFL2018

EPFL2017